World Hepatitis Day 2021 Webinar series

"World

In July the World Hepatitis Alliance hosted three webinars focusing on key topics in hepatitis elimination. View the webinars below. 

Webinar one: Hepatitis Can’t Wait- accelerating elimination. 

With so few countries on track to achieve hepatitis elimination by 2030 – we can’t wait to accelerate action toward this goal. 

This roundtable discussion will explore how we can generate momentum through innovation, prioritisation, collaboration and overcome the long-standing barriers that have stood in our way. 

Key discussion points:

  1. Overcoming the persistent barriers to testing, treatment and prevention 
  2. Empowering people affected by hepatitis to fight stigma and discrimination and to drive change by decision-makers
  3. Accelerating the decentralisation of services to bring them closer to the communities that need them
  4. Accelerating hepatitis elimination through cancer prevention, reduction of non-communicable diseases and the transformation to universal health coverage (UHC).
     



Webinar two: Policy makers Can’t Wait 

Roundtable discussion on how we can overcome the barriers in parliaments, governments, and health systems to fund and implement hepatitis elimination programmes.


Key discussion points:
1. What is standing in the way of countries acting on the global commitment to eliminate viral hepatitis by 2030? Is it only about finance?
2. How can we progress through these barriers towards positive action?
3. In countries where hepatitis elimination programmes are in place – what were the contributors to their success?
4. What are the messages which will resonate with parliamentarians and will motivate them towards action?
5. How can community activists and policy makers work together to make change happen?

 

 

Webinar three: Youth Can’t Wait 

Millions of young people around the world are living with viral hepatitis and they can’t wait for action. This event will amplify the voices of these young people, along with those dedicated to improving their lives and stopping future generations from being affected.


Discussion areas to include:
1. What is it like growing up with hepatitis and effect does it have on families?
2. How young people are already making a difference and how can we further harness their passion and energy to drive forward elimination?
3. What needs to be done to better support young people with hepatitis?

 

Latest News

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close